ERDHEIM-CHESTER DISEASE
Clinical trials for ERDHEIM-CHESTER DISEASE explained in plain language.
Never miss a new study
Get alerted when new ERDHEIM-CHESTER DISEASE trials appear
Sign up with your email to follow new studies for ERDHEIM-CHESTER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare immune diseases: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called cobimetinib in children and adults with Langerhans cell histiocytosis and similar disorders that have not responded to standard treatments. Cobimetinib blocks a faulty growth signal in cells, aiming to shrink tumors and slow disease progression. The…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: PHASE2 • Sponsor: Carl Allen • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Could a melanoma drug combo work for other rare cancers?
Disease control Recruiting nowThis study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with rare cancers that have a specific BRAF V600 mutation. About 30 people with various cancer types will receive the combination to see if it shrinks tumors or prevents growth for a…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 12, 2026 12:02 UTC
-
New registry aims to track rare immune diseases over time
Knowledge-focused Recruiting nowThis study creates a registry for up to 500 people with Erdheim-Chester disease and similar conditions. Researchers will collect health information, treatment details, and patient experiences to learn how these diseases progress and affect daily life. Some participants may also b…
Matched conditions: ERDHEIM-CHESTER DISEASE
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 22:05 UTC
-
Massive study tracks hidden toll of rare immune diseases
Knowledge-focused Recruiting nowThis study follows 6,000 people with histiocytic disorders (like Langerhans cell histiocytosis) to understand long-term health problems, pain, mental health, and causes of death. Researchers compare participants to healthy controls to identify factors that lead to new health issu…
Matched conditions: ERDHEIM-CHESTER DISEASE
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:56 UTC
-
New imaging agent could help spot Hard-to-See blood cancers
Knowledge-focused Recruiting nowThis early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like non-Hodgkin lymphoma and multiple myeloma) and rare histiocytic tumors. About 30 participants will receive the age…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:56 UTC